Revolution Med Prices Rare Disease Drug Rasonque at Nearly $40,000 Per Month
A new report examines whether insurance coverage and patient access programs can keep pace with the high cost of Revolution Med's newly approved rare disease treatment.
Results for "Rasonque"
6 stories found
Medical Experts Outline Updated Guidelines for 2026-2027 Flu and COVID Vaccinations
With both vaccines reformulated for the upcoming season, physicians provide targeted advice on eligibility, optimal timing, and priority groups to maximize public protection.
HealthBBCNYTNPR+8globe-and-maillsm-lvYahoobalkan-webnewsbeastThe Weektaiwan-newsmyjoyonline8d ago11 sources
U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates
The U.S. Food and Drug Administration has approved a breakthrough pancreatic cancer treatment that clinical trials show extends patient survival to a median of 13.2 months, marking a major advancement for one of the most difficult-to-treat cancers.
New England Journal of Medicine Publishes Phase 1/2 Data on Revolution Medicines' Daraxonrasib for NSCLC
Revolution Medicines has published early clinical trial results for its experimental drug daraxonrasib (RASONQUE) targeting metastatic non-small cell lung cancer, marking a significant step in evaluating its safety and efficacy profile.
FDA Approves Breakthrough Pancreatic Cancer Pill That Nearly Doubles Survival Rates
The U.S. Food and Drug Administration has approved a new once-daily oral medication for advanced pancreatic cancer, marking a significant clinical breakthrough that nearly doubled patient survival rates in trials. The approval has prompted analysts to raise price targets for associated biotechnology firms.